Product1 distinct publisher3 min readUpdated
Medly AI's $8m seed took the headlines. The government research contract running to 31 March 2027 is the document edtech product teams should actually read.
The Product Desk · Product desk

Compiled by The Product DeskSomething wrong?How this is made
Medly AI, a London exam-prep platform built by two former NHS doctors, has raised an $8m seed round led by Felix Capital, with existing backers Eka Ventures and Ada Ventures returning [1]. The more consequential paperwork is older and smaller: in June the company was one of eight suppliers picked from 53 bids for the AI Tutoring Tools Pioneers Programme, run by the Department for Science, Innovation and Technology with the Department for Education as delivery partner [2].
Each winner takes £300,000 excluding VAT on research contracts running to 31 March 2027, aimed at raising attainment among disadvantaged pupils in England [3]. That is roughly £2.4m across the cohort [1], which buys nothing at national scale and is not trying to. What it buys is a named customer, a named target population, and a date by which someone expects to see findings. Eight awards from 53 bids is a success rate of about 15% [2], which tells you the department had enough applicants to be selective and chose to spread the money thinly rather than back one horse.
The cohort composition is the other signal. Pearson, ElevenLabs and Eedi are also on the list [4]: an incumbent publisher, a voice model company, and a maths startup, in the same lot. The buyer is not procuring a product shape called "AI tutor". It is procuring tutoring capability from whoever can evidence it.
That matters because the evidence currently on offer from the sector is the kind that a research contract exists to replace. Medly says 74% of students who used it for last summer's GCSEs improved by at least one grade and 41% improved by two or more, figures drawn from a survey of its own users rather than an independent assessment [5]. Taken together those numbers imply about a third of respondents moved exactly one grade [4]. The company puts its largest subject gains at 46% and 43%, but its own website attributes the 46% to English Literature while the announcement attributes it to Physics [6]. It claims more than 400,000 users in the UK alone while its consumer site advertises "300,000+ students", a gap of a third [7][5].
The more serious work is unfinished. In June three members of the team published a preprint benchmarking 32,534 double-marked GCSE responses across 328 questions and five subjects, finding that leading off-the-shelf models agreed with examiners at least as closely as two examiners agreed with each other [8]. That paper tests general-purpose models rather than Medly's own marking stack and has not been peer reviewed [9]. A randomised controlled trial of more than 1,000 pupils in lower-attaining schools is complete but unpublished [10].
The product itself marks practice answers and explains where the marks went through a conversational interface [11], runs on what the company describes as a proprietary combination of seven large language models [12], and accepts stylus handwriting on a tablet, which matters in maths and chemistry where the working is the answer [13]. Medly intends to build its own models for UK and EEA marking and pedagogy rather than renting general-purpose ones indefinitely [14]. Meanwhile it has added the SAT in the US on top of GCSEs, A-levels and the IB, with APs and ACTs planned before year end [15].
Worth noting the proportions: £300,000 is about 18% of the £1.7m round Medly announced in February 2025 [16][3]. Nobody is taking this contract for the revenue.
Watch three things. Whether the completed RCT gets published, and whether it says what the user survey says. Whether the Pioneers Programme publishes comparable results across all eight suppliers before 31 March 2027, or whether the evidence stays proprietary. And whether the own-model plan ships before the contract ends, given the US expansion competing for the same engineers.
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Medly AI, a London exam-prep platform built by two former NHS doctors, raised an $8m seed round led by Felix Capital, with existing backers Eka Ventures and Ada Ventures returning.
Each winner takes £300,000 excluding VAT for research contracts running to 31 March 2027, aimed at raising attainment among disadvantaged pupils in England.
The product marks practice answers and explains where the marks went, through a conversational interface rather than a worksheet.
Handwriting recognition lets students work with a stylus on a tablet, which matters in maths and chemistry, where the working is the answer.
The seed round follows a £1.7m round announced in February 2025 and led by Eka Ventures.
In June, Medly was one of eight suppliers picked from 53 bids for the AI Tutoring Tools Pioneers Programme, run by the Department for Science, Innovation and Technology with the Department for Education as delivery partner.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Structural facts firm, performance evidence unverified
The procurement facts are specific and checkable in outline (eight of 53 bids, £300,000 excluding VAT each, contracts to 31 March 2027, named cohort peers), and a quantified marking benchmark exists. But every performance and scale claim rests on the vendor: the grade-improvement figures are a self-survey, the RCT is unpublished, the preprint measures general-purpose models rather than Medly's own stack and is not peer reviewed, and two company-sourced numbers contradict each other. One publisher, no primary programme documentation quoted.
Real government contract, self-reported user scale
Adoption has one hard anchor — a live DSIT/DfE research contract running to 31 March 2027 in English schools, placing Medly in a cohort with Pearson, ElevenLabs and Eedi — plus exam-board coverage expansion into the US SAT. Beyond that, scale is entirely company-stated and internally inconsistent (400,000 UK users versus 300,000+ advertised), and no school, district or paying-customer detail is given, so claimed reach cannot be treated as measured deployment.
Outcome and scale claims run ahead of the evidence
The promotional layer — 74% of students up at least one grade, 41% up two or more, 46%/43% subject gains, 400,000 UK users, a proprietary seven-model architecture — is materially stronger than what can be checked. The best available study benchmarks other vendors' general-purpose models, the RCT that would settle efficacy is unpublished, and the company's own figures conflict on both a subject attribution and a user count. The gap is moderate rather than extreme because the article itself flags each caveat and because the procurement facts underneath are concrete.
Funding-announcement framing with vendor-supplied metrics
The information flow is strongly interested: the news peg is the company's own round, the metrics originate with the company, and the only evaluative voices are the lead investor at Felix Capital and a returning investor at Eka, both of whom hold positions. The June preprint was authored by the company's own team. The government programme creates an additional incentive to publicise attainment claims before the March 2027 contract window closes. No adversarial or independent voice appears in the cluster.
Single publisher, one interested primary source
Everything here traces to one article from one publisher, itself largely reliant on company statements. The article's own scepticism improves reliability at the margins — it names the self-survey basis, the missing peer review, the unpublished RCT and the two internal inconsistencies — but nothing is independently corroborated, no primary procurement document is cited, and no second outlet is present to test the claims.
build
The demo-best voice engine finished last: 12,247 calls argue for buying on completion rate1 distinct publisher
build
48 startups, 4 known by name, 28 recommended by category1 distinct publisher
product
Pearson's inversion: in learning products, the correct answer can be the product failure1 distinct publisher
product
Adobe ships Firefly's audio tools with a licensing claim attached, not just better output2 distinct publishers
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 18, 2026